Subscribe To
Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated...
November 4, 2023, 5:37 pm
Kineta reports third quarter 2023 financial results and provides corporate update
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial enroll...
November 3, 2023, 8:01 pm
Why trupanion stock soared today
Trupanion easily exceeded estimates with its third-quarter report, including 22% quarterly revenue growth and a significantly narrowed net loss. Total...
November 3, 2023, 4:03 pm
Cardiol therapeutics reaches new milestone in phase ii study for recurrent pericarditis
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced it has successfully enrolled over 50% of the tar...
November 1, 2023, 8:41 am
Sagimet biosciences announces completion of enrollment of 120 patients for phase 3 clinical trial by its partner ascletis of denifanstat combined with bevacizumab for treatment of recurrent glioblasto
SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing ...
September 27, 2023, 8:05 pm
Sagimet biosciences announces completion of enrollment of 120 patients for phase 3 clinical trial by its partner ascletis of denifanstat combined with bevacizumab for treatment of recurrent glioblasto
SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing ...
September 27, 2023, 8:05 pm
Amazon.com executives named in ftc complaint over 'deceptive' prime processes
The Federal Trade Commission (FTC) on Wednesday announced that it has added three senior Amazon.com Inc (NASDAQ:AMZN) executives as defendants as it ...
September 21, 2023, 11:47 am
Seelos therapeutics' stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpoint
Seelos Therapeutics Inc.'s stock SEEL tumbled 36% in premarket trade Wednesday, after the company reported promising results from a trial of a treatme...
September 20, 2023, 7:46 am
Arway.ai lands contract with 2nd largest academic institute in turkey
ARway.ai (CSE:ARWY, OTCQB:ARWYF) announced it has signed a contract with Turkish university Süleyman Demirel Üniversitesi aimed at helping students...
September 7, 2023, 8:36 am
Okyo pharma dry eye disease trial reaches enrollment milestone; topline data expected by year-end
OKYO Pharma Ltd (NASDAQ:OKYO) said it has enrolled 90% of patients in its 240-patient Phase 2 evaluatin...
August 30, 2023, 8:39 am
Statehouse reports second quarter 2023 financial results
Q2 Revenue increased 2% sequentially to $25.3 million with a 15% improvement in gross margin for a consolidated Q2 Gross Margin of 49.9% Generated $63...
August 29, 2023, 10:04 pm
Avila welcomes the largest incoming class in institutional history
While many colleges and universities are struggling with enrollment numbers, Avila University enrolled ...
August 24, 2023, 9:19 pm
Gilead sciences told by fda to pause patient enrollment in leukemia drug trials
Gilead Sciences, Inc. (NASDAQ:GILD) said the Food and Drug Administration (FDA) has put a clinical hold on its studies evaluating its investigation an...
August 21, 2023, 10:41 am
Gilead says fda hits pause on study of leukemia treatment
Gilead Sciences Inc. GILD, -0.81% said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a ...
August 21, 2023, 8:47 am
Anika reports second quarter 2023 financial results
Double Digit Q2 Revenue Growth Driven by Strong OA Pain Management Growth of 22%; Raising Low-End of Full-Year Guidance Range on Positive Year-to-Date...
August 8, 2023, 8:05 pm
Altimmune announces initiation of phase 2b impact trial evaluating the efficacy and safety of pemvidutide in non-alcoholic steatohepatitis (nash)
GAITHERSBURG, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that ...
August 1, 2023, 11:30 am
Maxim upbeat on atossa therapeutics after recent updates
Analysts at Maxim Group have reiterated a 'buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) shares after the biotech recently announced an enroll...
July 11, 2023, 8:06 am
Atossa therapeutics provides update on phase 2 breast density trial enrollment
Atossa Therapeutics Inc (NASDAQ:ATOS) announced that 170 patients have been enrolled across its ongoing...
July 10, 2023, 10:37 am
Revive therapeutics' study on safety and efficacy of bucillamine to treat covid 19 shows no statistical significance
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said the results of its Phase 3 clinical trial evaluating the safety and efficacy of oral Bucillamine i...
July 6, 2023, 8:07 am
Maia biotechnology: progress in the thio-101 trial sets up a 2023 catalyst
MAIA's THIO-101 trial of 6-thio-2-deoxyguanosine in non-small cell lung cancer had enrolled 29 patients...
July 1, 2023, 2:41 am